Sanofi: FDA Approves Use of 0.5 mL Dose of Influenza Vaccine in Children as Young as 6 Months of Age

Originally Published by Sanofi.

The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) to include children age 6 through 35 months. Sanofi Pasteur, the vaccine division of Sanofi, will have the 0.5 mL dose, in addition to the 0.25 mL dose, available for the upcoming 2019-20 season for this expanded age range.


“Offering pediatricians the convenience of the same 0.5 mL dose option for children, may help streamline immunization efforts,” said Dr. David P. Greenberg, Regional Medical Head North America, Sanofi Pasteur. “The potentially life-threatening effects of influenza in children reported during the 2017-18 season, especially among those who were not vaccinated, is sobering. We commit ourselves every day to bring solutions to help meet ongoing public health needs related to influenza, especially among vulnerable groups such as young children.”

Today’s approval is supported by clinical data from a Phase IV safety and immunogenicity study conducted in nearly 2,000 children, which demonstrated that one or two doses of 0.5 mL of vaccine in children 6 through 35 months of age had a safety profile that was comparable to one or two doses of 0.25 mL of vaccine with no new safety concerns observed, and induced a robust immune response. Detailed results were presented at the Pediatric Academic Societies meeting in April 2018, as well as at the Advisory Committee on Immunization Practices meeting and the American Academy of Family Physicians Family Medicine Experience conference in October 2018.

Sanofi Pasteur’s flu vaccine portfolio includes options to help protect all eligible patients from influenza. In addition to Fluzone Quadrivalent vaccine, the product portfolio includes Flublok Quadrivalent (influenza vaccine) and Fluzone High-Dose (influenza vaccine), the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators in randomized controlled trials. In these same trials, the most common local and systemic adverse reactions to Flublok Quadrivalent and Fluzone High-Dose vaccines include pain at the injection site, headache and myalgia.

Health care providers can place 2019-20 reservations for all Sanofi Pasteur vaccines, including the 0.5 mL presentations of Fluzone Quadrivalent vaccine for use in all appropriate pediatric patients via www.VaccineShoppe.com. The 0.25 mL dose of Fluzone Quadrivalent vaccine will remain available for 2019-20 reservations.

Latest News

Boeing Company Expands Sustainability Alliance With Etihad Airways To Drive Innovation in the Aviation Industry

Originally published at boeing.mediaroom.com. Boeing Company ranked No. 17 on The DiversityInc Top 50 Companies for Diversity list in 2021.   On Nov. 15, Boeing and Etihad Airways announced they will expand the companies’ deep collaboration towards environmental goals. Centered on the airline’s 787 Dreamliner fleet, the new memorandum of understanding…

KPMG on Celebrating Its Military Veteran Workforce

Originally published at info.kpmg.us. KPMG ranked No. 16 on The DiversityInc Top 50 Companies for Diversity list in 2021.   As we commemorate Veterans Day and honor all who served in the United States Armed Forces, we spotlight Air Force veteran Heather Paquette and Marine Corps veteran Joe Bergeron, two KPMG professionals who are members…